Skip to content
Review

Pathophysiology of aldosterone dysregulation in difficult-to-control hypertension.

Oct 2026 · American Journal of Hypertension · Vol 39 Supplement_1, pp. S11-S17 · 0 citations
Medicine

TL;DR

Recognizing aldosterone dysregulation as a systemic cardio-renal-metabolic disorder has important implications for risk stratification and targeted therapies with a focus on cardiovascular outcomes.

View source

Similar papers

Review Oct 2026

Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies.

This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs).

Mehmet Kanbay, Rama Al-Shiab, Ermeena Shah et al. · 0 citations
Review Open access Jun 2026

Endothelin antagonism: a new era for resistant hypertension

ABSTRACT Hypertension is a major global health burden and a leading contributor to cardiovascular disease and chronic kidney disease (CKD). Despite the availability of multiple antihypertensive therapies, blood pressure control remains suboptimal, and a significant proportion of patients develop resistant hypertension,...

Gavin B. Chapman, Dan Pugh, N. Dhaun · 0 citations
Review Oct 2026

Cortisol in cardio-kidney-metabolic disease.

The epidemiology and mechanisms linking cortisol excess to CKM dysfunction are summarized, and the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk is highlighted.

Muhammad Shahzeb Khan, Muhammad Sameer Arshad, Deepak L. Bhatt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.